Sirolimus-based regimen is associated with decreased expression of glomerular vascular endothelial growth factor

Nephrology Dialysis Transplantation

Volumn 27, Issue 1, 2012, Pages 411-416

  Vuiblet, Vincent ^a   Birembaut, Philippe ^a   Franois, Arnaud ^b   Cordonnier, Carole ^c   Noel, Laure Helene ^d   Goujon, Jean Michel ^e   Paraf, Francois ^f   MacHet, Marie Christine ^g   Girardot Seguin, Sandrine ^h   Lebranchu, Yvon ^g   Rieu, Philippe ^a  

^a REIMS UNIVERSITY HOSPITAL   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e POITIERS UNIVERSITY HOSPITAL   (France)

^f LIMOGES UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF TOURS   (France)

^h Roche SAS   (France)

Author keywords

kidney transplantation; sirolimus; vascular endothelial growth factor

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; VASCULOTROPIN;

ADULT; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLOMERULUS; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY GLOMERULUS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROGNOSIS; PROSPECTIVE STUDIES; PROTEINURIA; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84856639711     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr261     Document Type: Article

References (39)

1. Buchler M, Caillard S, Barbier S et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 2522-2531 (Pubitemid 47561618)
2. Flechner SM, Goldfarb D, Modlin C et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070-1076 (Pubitemid 35216097)
3. Kreis H, Cisterne JM, Land W et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252-1260 (Pubitemid 30238708)
4. Kreis H, Oberbauer R, Campistol JM et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809-817 (Pubitemid 38294812)
5. Larson TS, Dean PG, Stegall MD et al. Complete avoidance of calci-neurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514-522 (Pubitemid 43382137)
6. McTaggart RA, Tomlanovich S, Bostrom A et al. Comparison of outcomes after delayed graft function: sirolimus-based versus other calcineurin-inhibitor sparing induction immunosuppression regimens. Transplantation 2004; 78: 475-480 (Pubitemid 39095417)
7. Morath C, Arns W, Schwenger V et al. Sirolimus in renal transplantation. Nephrol Dial Transplant 2007; 22 (Suppl 8): viii61-viii65
8. Lebranchu Y, Thierry A, Toupance O et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009; 9: 1115-1123
9. Koromilas AE, Lazaris-Karatzas A, Sonenberg N. mRNAs containing extensive secondary structure in their 5# non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E. Embo J 1992; 11: 4153-4158
10. Phung TL, Ziv K, Dabydeen D et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006; 10: 159-170 (Pubitemid 44175906)
11. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135 (Pubitemid 34155123)
12. Basu A, Datta D, Zurakowski D et al. Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development. J Biol Chem 2010; 285: 25196-25202
13. Brown LF, Berse B, Tognazzi K et al. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 1992; 42: 1457-1461
14. Grone HJ, Simon M, Grone EF. Expression of vascular endothelial growth factor in renal vascular disease and renal allografts. J Pathol 1995; 177: 259-267
15. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136 (Pubitemid 351398487)
16. Eremina V, Sood M, Haigh J et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716 (Pubitemid 36278589)
17. Reynolds JC, Agodoa LY, Yuan CM et al. Thrombotic microangiop-athy after renal transplantation in the United States. Am J Kidney Dis 2003; 42: 1058-1068 (Pubitemid 37322923)
18. Sartelet H, Toupance O, Lorenzato M et al. Sirolimus-induced throm-botic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant 2005; 5: 2441-2447
19. Diekmann F, Rovira J, Carreras J et al. Mammalian target of rapamy-cin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. J Am Soc Nephrol 2007; 18: 2653-2660 (Pubitemid 47531192)
20. Keller K, Daniel C, Schocklmann H et al. Everolimus inhibits glo-merular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy. Nephrol Dial Transplant 2006; 21: 2724-2735 (Pubitemid 44542224)
21. Letavernier E, Bruneval P, Vandermeersch S et al. Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 2009; 24: 630-638
22. Reinders ME, Rabelink TJ, Briscoe DM. Angiogenesis and endothe-lial cell repair in renal disease and allograft rejection. J Am Soc Neph-rol 2006; 17: 932-942
23. Dormond O, Madsen JC, Briscoe DM. The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. J Biol Chem 2007; 282: 23679-23686 (Pubitemid 47311969)
24. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003-2017 (Pubitemid 38669987)
25. Simon M, Grone HJ, Johren O et al. Expression of vascular endothe-lial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 1995; 268: F240-F250
26. Pilmore HL, Eris JM, Painter DM et al. Vascular endothelial growth factor expression in human chronic renal allograft rejection. Transplantation 1999; 67: 929-933 (Pubitemid 29169143)
27. Shihab FS, Bennett WM, Yi H et al. Expression of vascular endothe-lial growth factor and its receptors Flt-1 and KDR/Flk-1 in chronic cyclosporine nephrotoxicity. Transplantation 2001; 72: 164-168 (Pubitemid 32652525)
28. Lemos FB, Ijzermans JN, Zondervan PE et al. Differential expression of heme oxygenase-1 and vascular endothelial growth factor in cadaveric and living donor kidneys after ischemia-reperfusion. J Am Soc Nephrol 2003; 14: 3278-3287 (Pubitemid 37509304)
29. Izzedine H, Rixe O, Billemont B et al. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 2007; 50: 203-218 (Pubitemid 47095077)
30. Foster RR. The importance of cellular VEGF bioactivity in the development of glomerular disease. Nephron Exp Nephrol 2009; 113: e8-e15
31. Kim YG, Suga SI, Kang DH et al. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiop-athy. Kidney Int 2000; 58: 2390-2399
32. Foster RR, Hole R, Anderson K et al. Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am J Physiol Renal Physiol 2003; 284: F1263-F1273 (Pubitemid 36578454)
33. Letavernier E, Bruneval P, Mandet C et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007; 2: 326-333
34. de Vriese AS, Tilton RG, Elger M et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993-1000 (Pubitemid 32378340)
35. Lebranchu Y, Thierry A, Thervet E et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF: 4-year results of the POST-CONCEPT study. Am J Transplant 2011, in press
36. Reinders ME, Fang JC, Wong W et al. Expression patterns of vascular endothelial growth factor in human cardiac allografts: association with rejection. Transplantation 2003; 76: 224-230 (Pubitemid 36877141)
37. Lemstrom KB, Krebs R, Nykanen AI et al. Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. Circulation 2002; 105: 2524-2530 (Pubitemid 34568975)
38. Raisky O, Nykanen AI, Krebs R et al. VEGFR-1 and-2 regulate inflammation, myocardial angiogenesis, and arteriosclerosis in chronically rejecting cardiac allografts. Arterioscler Thromb Vasc Biol 2007; 27: 819-825 (Pubitemid 46606712)
39. Denton MD, Magee C, Melter M et al. TNP-470, an angiogenesis inhibitor, attenuates the development of allograft vasculopathy. Transplantation 2004; 78: 1218-1221 (Pubitemid 39426443)